Cell Panel Screening Service

The Cell Panel Screening technique is employed to assess the therapeutic impacts of test compounds on a variety of human cancer cell lines. LeadQuest Biotech’s Cell Bank houses an extensive collection of over 800 cell strains, including a comprehensive array of more than 500 human tumor cell lines specifically for Cell Panel screening. This approach spans more than 30 cancer types, encompassing a wide range of prevalent malignancies such as lung, lymphoma, gastric, breast, prostate, and colorectal cancers.

Application

Identification of responsive tumor cell lines.
Ascertainment of suitable indications.
Selection of the most responsive tumor cell lines for cell modeling or patient-derived xenografts (PDX).
Assessment of genomic profiles to predict responses to anti-cancer therapies (optional).
Drug Efficacy Evaluation of test compounds on different human cancer cell lines.

List of Service

1.Customizable Cell Panels

1)LeadQuest Biotech Cell Bank maintains a vast repository of over 500 human tumor cell lines, with an addition of 50 cell lines monthly.

2)Collaborators may select any human tumor cell lines from our bank to assemble a customized Cell Panel for their specific compound screening.

2.Standard Cell Panels

A selection of 170 human tumor cell lines representing 21 tumor types.

Study Design

1.Controls

1)High control: solvent.

2)Low control: culture medium.

3)Positive control agent: staurosporine.

2.Sample Requirements

Generally, a 100 µL stock solution at 1000× the maximum test concentration (solid compounds should be prepared accordingly).

3.Biomarker and Proteolysis Analysis (optional)

Workflow

Inoculation of cells in 384-well plates.
Overnight incubation, followed by automated addition of test compounds via ECHO.
Maintenance of cells under COA-specified conditions.
Utilization of the CellTiter-Glo assay.

Advantages

Immediate initiation of testing upon receipt.
Cost-effective budgeting.
Expedited experimental timeline.
Consistent, reproducible data.
Compatibility with both single and combination drug assessments.
Comprehensive bioinformatics analysis (optional).